產(chǎn)品優(yōu)勢：

（1）自主化、國產(chǎn)化的原研體系；供貨穩(wěn)定，高性價比；

（2）支持臨床級/藥品級細胞培養(yǎng)，培養(yǎng)的iPSC細胞通過了中國食品藥品檢定研究院質(zhì)量復(fù)核；iPSC來源功能藥物通過了IND默示許可。

產(chǎn)品規(guī)格

細胞形態(tài)與生長情況

VTN包被蛋白連續(xù)培養(yǎng)的hiPSC（P20）細胞形態(tài)圖示，使用hiPSC/hESC 培養(yǎng)基-ncEpic培養(yǎng)。

A、B、C分別為培養(yǎng)第1、2、4天時，顯微鏡下hiPSC的形態(tài)圖示，標(biāo)尺：200μm。

文獻引用

Base editing-mediated splicing correction therapy for spinal muscular atrophy

2020. Xiang Lin, et al.. Cell Research(IF 46.297).

Embryonic Stem Cell Derived Small Extracellular Vesicles Modulate Regulatory T Cells to Protect against Ischemic Stroke

2020. Yuguo Xia, et al.. ACS Nano(IF 18.027).

Inducible Pluripotent Stem Cel-Derived Small Extracellular Veicles Rejuvenate Senescent Blood-Brain Barier to Protect against schemic Stroke in Aged..

2022. Qing Li, et al. ACS Nano(IF 18.0280).

ESC‐sEVs Rejuvenate Senescent Hippocampal NSCs by Activating Lysosomes to Improve Cognitive Dysfunction in Vascular Dementia

2020. Guowen Hu, et al.. Advanced Science(IF 17.521).

Human ESC-sEVs alleviate age-related bone loss by rejuvenating senescent bone marrow-derived mesenchymal stem cels

2020. Liangzhi Gong, et al. Journal of Extracellular Vesicles(lF 17.3378)

更多文獻引用，請撥打021-61283010詳細咨詢